Sarepta Therapeutics and Summit Enter into Exclusive License and Collaboration Agreement

Sarepta Therapeutics and Summit Enter into Exclusive License and Collaboration Agreement

Firm News

WilmerHale client Summit Therapeutics plc and Sarepta Therapeutics announced that they have entered into an exclusive license and collaboration agreement granting Sarepta rights in Europe, as well as in Turkey and the Commonwealth of Independent States, to Summit's utrophin modulator pipeline, including its lead clinical candidate, ezutromid, for the treatment of Duchenne muscular dystrophy. As part of the agreement, Summit receives $40 million upfront, with potential future ezutromid-related milestone payments totaling up to $522 million plus royalties. Sarepta also obtains an option to license Latin American rights to Summit's utrophin modulator pipeline and Summit retains commercialization rights in all other countries. 

The WilmerHale team representing Summit in this transaction included Partners Steve Barrett and Brian Johnson, Senior Associates Mat Trachok and Scott Lunin and Associate Alex Civetta

Read the formal press release announcing the agreement.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.